Post by AIxBiotech

Your rare disease pipeline valuation model just changed. A single injection. Ten patients. Every one of them can hear now. Not a promising signal. A production result published in Nature Medicine. Our team at AIxBiotech read the Karolinska Institutet data closely. Researchers delivered a working copy of the OTOF gene directly into the cochlea using an AAV vector. Average hearing threshold improved from 106 decibels to 52 decibels. All ten patients improved. No serious adverse events. Otovia Therapeutics (https://lnkd.in/eaNbFrnj), the Suzhou-based company that developed the therapy, raised close to 100 million yuan in January 2026. That funding round looks different now that the Phase I data is this clean. The commercial signal here is bigger than one company. Eli Lilly (https://lnkd.in/gn5rB_r9) committed $2.4 billion to hearing loss gene therapy in the past 12 months across two separate deals with Seamless Therapeutics (https://lnkd.in/etGX-MqV) and Rznomics. The Karolinska data validates both bets. One-time cures also break the chronic treatment revenue model entirely. Reimbursement logic shifts from annual cost to lifetime value. Outcome-based payer frameworks are no longer optional. Market access teams that have never built a one-time dosing dossier need to start now. OTOF is proven. GJB2 and TMC1 are next, and the research team said so publicly. The acquirer race for rare disease hearing loss assets starts this week. Based on publicly available information. This analysis covers non-proprietary, publicly disclosed data only. 🤖 AI x Biotech: No hype. Concrete signals for biotech executives and commercial teams. Follow @aixbiotech for daily updates — and to keep us going.